home / stock / kttaw / kttaw quote
Last: | $0.014 |
---|---|
Change Percent: | 10.71% |
Open: | $0.0125 |
Close: | $0.014 |
High: | $0.014 |
Low: | $0.0125 |
Volume: | 8,194 |
Last Trade Date Time: | 04/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.014 | $0.0125 | $0.014 | $0.014 | $0.0125 | 8,194 | 04-17-2024 |
$0.0123 | $0.0123 | $0.0123 | $0.0123 | $0.0123 | 2,000 | 04-16-2024 |
$0.015 | $0.015 | $0.015 | $0.015 | $0.015 | 5,115 | 04-09-2024 |
$0.0123 | $0 | $0.0123 | $0 | $0 | 30 | 04-08-2024 |
$0.0123 | $0 | $0.0123 | $0 | $0 | 10 | 04-04-2024 |
$0.0123 | $0.0123 | $0.0123 | $0.0123 | $0.0123 | 10,000 | 04-03-2024 |
$0.0123 | $0 | $0.0123 | $0 | $0 | 1 | 04-02-2024 |
$0.0123 | $0.0123 | $0.0123 | $0.0123 | $0.0123 | 1,250 | 04-01-2024 |
$0.0123 | $0 | $0.0123 | $0 | $0 | 4 | 03-28-2024 |
$0.0123 | $0.0123 | $0.0123 | $0.0123 | $0.0123 | 2,507 | 03-26-2024 |
$0.012892 | $0.012892 | $0.012892 | $0.012892 | $0.012892 | 250 | 03-25-2024 |
$0.0123 | $0.0123 | $0.0123 | $0.0136 | $0.0123 | 1,729 | 03-20-2024 |
$0.0123 | $0.0123 | $0.0123 | $0.0123 | $0.0123 | 153 | 03-19-2024 |
$0.0126 | $0.0126 | $0.0126 | $0.0126 | $0.0126 | 10,000 | 03-18-2024 |
$0.0126 | $0.0126 | $0.0126 | $0.0126 | $0.0126 | 254 | 03-14-2024 |
$0.013815 | $0 | $0.013815 | $0 | $0 | 29 | 03-13-2024 |
$0.013815 | $0 | $0.013815 | $0 | $0 | 1,000 | 03-12-2024 |
$0.013815 | $0.013815 | $0.013815 | $0.013815 | $0.013815 | 2,243 | 03-11-2024 |
$0.019 | $0.019 | $0.019 | $0.019 | $0.019 | 1,549 | 03-07-2024 |
$0.0119 | $0.0119 | $0.0119 | $0.0119 | $0.0119 | 1,000 | 03-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Warrant Company Name:
KTTAW Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the tr...
SOUTH SAN FRANCISCO, Calif. and MIAMI, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the ...
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europe in the coming months -- -- Preliminary interim data expected in 2H 2024 -- SOUTH SA...